Search

Your search keyword '"Bühnen, Ina"' showing total 15 results
Start Over Author "Bühnen, Ina" Publication Year Range Last 3 years
15 results on '"Bühnen, Ina"'

2. Low B‐cell content is associated with a CD73 ‐low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma

Author

Grund, Johanna, primary, Iben, Katharina, additional, Reinke, Sarah, additional, Bühnen, Ina, additional, Plütschow, Annette, additional, Müller‐Meinhard, Berit, additional, Garcia Marquez, Maria A., additional, Schlößer, Hans A., additional, von Tresckow, Bastian, additional, Kellermeier, Fabian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Bröckelmann, Paul J., additional, and Klapper, Wolfram, additional

Published
2023
Full Text
View/download PDF

3. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., Bühnen, Ina, Plütschow, Annette, Kobe, Carsten, Dietlein, Markus, Wendtner, Clemens‐Martin, Thorspecken, Sven, Topp, Max S., Mauser, Mareike, von Tresckow, Bastian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, and Tresckow, Bastian

Subjects
Cancer Research, Oncology, Medizin, Hematology, General Medicine
Published
2022

4. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Author

Bröckelmann, Paul J., primary, Bühnen, Ina, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Herhaus, Peter, additional, Halbsguth, Teresa V., additional, Schaub, Valdete, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Bormann, Matthias, additional, Dickhut, Andreas, additional, Kaul, Helen, additional, Fuchs, Michael, additional, Kobe, Carsten, additional, Baues, Christian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2022
Full Text
View/download PDF

5. Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Bühnen, Ina, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Herhaus, Peter, additional, Halbsguth, Teresa V, additional, Schaub, Valdete, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Bormann, Matthias, additional, Dickhut, Andreas, additional, Kaul, Helen, additional, Fuchs, Michael, additional, Kobe, Carsten, additional, Baues, Christian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2022
Full Text
View/download PDF

6. P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

Author

Voltin, Conrad-Amadeus, primary, Kreissl, Stefanie, additional, Kaul, Helen, additional, Bühnen, Ina, additional, Mettler, Jasmin, additional, Pabst, Thomas, additional, Eichenauer, Dennis A., additional, Fuchs, Michael, additional, Diehl, Volker, additional, Dietlein, Markus, additional, Engert, Andreas, additional, Borchmann, Peter, additional, and Kobe, Carsten, additional

Published
2022
Full Text
View/download PDF

7. T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

Author

Eichenauer, Dennis A., primary, Bühnen, Ina, additional, Fuchs, Michael, additional, Greil, Richard, additional, Moccia, Alden, additional, Zijlstra, Josée. M., additional, Hartmann, Sylvia, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2022
Full Text
View/download PDF

8. Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann‐Grill, Karolin, additional, Kobbe, Guido, additional, Hahn, Dennis, additional, Schroers, Roland, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Boger, Regina, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch‐Ullrich, Kathleen, additional, Griesinger, Frank, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J., additional

Published
2022
Full Text
View/download PDF

9. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.

Author

Bröckelmann, Paul J., Bühnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa V., Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan, Bormann, Matthias, Dickhut, Andreas, Kaul, Helen, Fuchs, Michael, Kobe, Carsten, Baues, Christian, Borchmann, Peter, Engert, Andreas, and von Tresckow, Bastian

Published
2023
Full Text
View/download PDF

10. Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma

Author

Kreissl, Stefanie, primary, Voltin, Conrad‐Amadeus, additional, Kaul, Helen, additional, Bühnen, Ina, additional, Mettler, Jasmin, additional, Pabst, Thomas, additional, Eichenauer, Dennis A., additional, Fuchs, Michael, additional, Diehl, Volker, additional, Dietlein, Markus, additional, Engert, Andreas, additional, Borchmann, Peter, additional, and Kobe, Carsten, additional

Published
2021
Full Text
View/download PDF

11. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann-Grill, Karolin, additional, Kobbe, Guido, additional, Wilhelm, Martin, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William Hermann, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch-Ulrich, Kathleen, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J, additional

Published
2021
Full Text
View/download PDF

13. Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma.

Author

Kreissl, Stefanie, Voltin, Conrad‐Amadeus, Kaul, Helen, Bühnen, Ina, Mettler, Jasmin, Pabst, Thomas, Eichenauer, Dennis A., Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, Borchmann, Peter, and Kobe, Carsten

Subjects
POSITRON emission tomography, HODGKIN'S disease, BONE marrow, PROGRESSION-free survival, CLINICAL trials
Abstract

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Keywords: bone marrow involvement; Hodgkin lymphoma; intensive chemotherapy; positron emission tomography; prognosis EN bone marrow involvement Hodgkin lymphoma intensive chemotherapy positron emission tomography prognosis e5 e8 4 03/30/22 20220401 NES 220401 Newly diagnosed advanced-stage Hodgkin lymphoma (HL) has become a curable malignancy in the vast majority of patients.1,2 With response-adapted treatment comprising four or six cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) in escalated dose (eBEACOPP), outstanding cure rates are achieved through a comparatively short and safe treatment approach.3,4 Around 5 to 15% of HL patients present with bone marrow (BM) involvement, as assessed by conventional biopsy.5-7 According to the Ann Arbor classification, BM involvement reflects a high tumour burden and therefore defines stage IV disease.8 Positron emission tomography (PET) using SP 18 sp F-fluoro-2-deoxy-d-glucose (FDG) has demonstrated superior sensitivity compared to BM biopsy.9-11 In paediatric advanced HL, only individuals showing three or more BM lesions were assumed to be at higher risk for progression or relapse.12 Yet, there are insufficient data available to establish whether this also holds true for adult patients receiving intensive first-line treatment. PET imaging was shown to identify BM lesions at a higher sensitivity than biopsy of the iliac bone and has become part of diagnostic work-up in most countries.15 Current study protocols no longer recommend BM biopsy in PET-negative individuals. [Extracted from the article]

Published
2022
Full Text
View/download PDF

14. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.

Author

Eichenauer, Dennis A., Bühnen, Ina, Kreissl, Stefanie, Goergen, Helen, Fuchs, Michael, von Tresckow, Bastian, Rosenwald, Andreas, Klapper, Wolfram, Hansmann, Martin‐Leo, Möller, Peter, Bernd, Heinz‐Wolfram, Feller, Alfred C., Engert, Andreas, Borchmann, Peter, and Hartmann, Sylvia

Subjects
*HODGKIN'S disease, *POSITRON emission tomography, *HISTOPATHOLOGY, *PROGRESSION-free survival, *OVERALL survival, *NEUROECTODERMAL tumors
Abstract

Summary: We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET‐2) tended to be more common (P = 0·1078). Five‐year progression‐free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET‐2‐guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET‐2‐guided escalated BEACOPP. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

15. Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Author

Bröckelmann, Paul J, Bühnen, Ina, Herhaus, Peter, Meissner, Julia, Trautmann-Grill, Karolin, Müller, Horst, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas, and Behringer, Karolin

Abstract

Background: First-line treatment of patients with classical Hodgkin lymphoma (HL) with anti-PD1 antibodies in combination with AVD chemotherapy is highly effective across risk-groups. Based on encouraging phase II and ongoing phase III trials, anti-PD1 based first-line treatment may hence soon become a first-line treatment option. To date, no data on fertility and gonadal function after anti-PD1 based first-line HL treatment is available. Herein, we present data on pregnancies and gonadal function in patients treated within the randomized GHSG phase II NIVAHL trial.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results